1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024

The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024

  • August 2016
  • 117 pages
  • ID: 3306971
  • Format: PDF
  • Persistence Market Research

Summary

Table of Contents

Bacterial conjunctivitis is a commonly encountered eye problem across the world, caused by various bacterial strains such as streptococci, staphylococci, chlamydial, and gonococci organisms. The majority of the cases of bacterial conjunctivitis are self-limited and acute and not a major cause of morbidity. This study provides market analysis for various antibacterial drug classes used for the treatment of bacterial conjunctivitis. The stakeholders of this study comprise established pharmaceutical companies involved in the commercialization of antibacterial drugs as well as new participants who wish to enter the U.S. market.

This market study provides a complete analysis of the bacterial conjunctivitis drugs market in the U.S. and helps in identifying various market governing factors. The market overview section provides exhaustive information of the incidence rate of bacterial conjunctivitis, list of API manufacturers, patent challenges, market trends such as drivers, restraints, and growth opportunities that currently control the dynamics of the overall market. The section also recommends and predicts the future conditions of the market. Market strategy tools such as event impact assessment and Porter’s Five Forces analysis have also been incorporated in this report to provide balanced analysis about the level of competition within the bacterial conjunctivitis drugs market in the U.S. Executive summary provided in the report encapsulates comprehensive insights about every segment considered in this study. Besides, it includes a market snapshot, which offers a glimpse into the current scenario of the bacterial conjunctivitis drugs market in the U.S. in terms of current and future market size along cumulative growth rate. Additionally, this study includes a regulatory framework segment wherein the overall regulatory scenario of the U.S. drugs policy has been described. Participant analysis tools such as market share analysis have also been included in the market overview section of the report to deliver a broad spectrum of the overall market scenario in the bacterial conjunctivitis drugs market in the U.S.

The bacterial conjunctivitis drugs market in the U.S. has been segmented based on various antibacterial drug classes. The market is segmented into major types of antibacterial drugs such as fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones segment has been sub-segmented into ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, and besifloxacin. Aminoglycosides have been sub-segmented into tobramycin and gentamycin. Macrolides has been divided into erythromycin and azithromycin. The others segment is analyzed cumulatively, considering bacitracin, fusidic acid, and ceftriaxone within this class. The market size for the period from 2012 to 2024 has been provided for each of the major drug classes mentioned above in terms of USD million. Along with the market size that were projected considering 2013 as the base year and 2012 as the historical year, the CAGR (%) of each market segment for the forecast period from 2012 to 2018 and 2018 to 2024 have also been provided.

The report concludes with detailed profiles of leading players in the bacterial conjunctivitis drugs (antibacterials) market in the U.S. The study profiles the companies in terms of overview, financial overview, product portfolio, business strategies, and recent developments. Major organizations profiled in this report include Actavis plc, Akorn, Inc., Bayer AG, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc. Additionally, market share analysis that has been provided in context with the major pharmaceuticals operating in the market would help new participants to understand the key business perceptions and frameworks and to identify the specific product lines of the existing companies to establish a strong foothold in the bacterial conjunctivitis drugs market in the U.S.

The U.S. bacterial conjunctivitis drugs market is segmented as follows:

U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class
Fluoroquinolones
Ciprofloxacin
Ofloxacin
Levofloxacin
Moxifloxacin
Gatifloxacin
Besifloxacin
Aminoglycosides
Tobramycin
Gentamycin
Macrolides
Erythromycin
Azithromycin
Others
U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment
Vancomycin Ophthalmic Ointment
Early Stage (Phase I and Phase II trials) – Tabular Representation

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on